(CercleFinance.com) – The biotechnology company Sensorion announces the extension for a period of five years of the framework research partnership agreement signed in 2019 with the Pasteur Institute, involving its Hearing Institute research center.
This partnership grants Sensorion an exclusive licensing option to develop and commercialize gene therapy drug candidates from collaborative projects to address unmet needs in hearing.
Two development programs are currently being carried out within this framework, namely SENS-501 (OTOF-GT) and GJB2-GT. Sensorion submitted an application in July 2023 for SENS-501 to initiate a phase 1/2 clinical trial in the UK and EU.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
